Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016', provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic (Essential) Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic (Essential) Hypertension - Products under Development by Companies 14
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15
Actelion Ltd 15
Bayer AG 16
Chong Kun Dang Pharmaceutical Corp. 17
Daiichi Sankyo Company, Limited 18
Eli Lilly and Company 19
HanAll Biopharma Co., Ltd. 20
Innopharmax Inc. 21
Lee's Pharmaceutical Holdings Limited 22
PhaseBio Pharmaceuticals, Inc. 23
Quantum Genomics SA 24
Takeda Pharmaceutical Company Limited 25
Idiopathic (Essential) Hypertension - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
(amlodipine besylate + candesartan cilexetil) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(atorvastatin calcium + losartan potassium) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(candesartan cilexetil + nifedipine) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
azilsartan medoxomil - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
carvedilol phosphate CR - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CS-3150 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
lisinopril - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LY-2623091 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
PB-1046 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
PB-1120 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
QGC-001 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
rostafuroxin - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Idiopathic (Essential) Hypertension - Dormant Projects 57
Idiopathic (Essential) Hypertension - Product Development Milestones 59
Featured News & Press Releases 59
Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 59
Jun 12, 2013: Lee's Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2016 15
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2016 16
Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 17
Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 18
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2016 19
Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 20
Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H2 2016 21
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 22
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 23
Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H2 2016 24
Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Idiopathic (Essential) Hypertension - Dormant Projects, H2 2016 57
Idiopathic (Essential) Hypertension - Dormant Projects (Contd..1), H2 2016 58